May 25, 2020International Journal of CancerOpen Access

Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors

View Full Paper

Ask AI

Bookmark

Why the study?

QTc interval prolongation can occur with tyrosine kinase inhibitors, but comparative real-world analyses on its incidence and complication rates are scarce.

Does tyrosine kinase inhibitor therapy cause QTc prolongation and life-threatening arrhythmias in cancer patients?

Population

618 cancer patients treated with TKI therapy with at least two ECGs at Mayo Clinic

Comparison

Different TKI types

Design

Retrospective cohort study

Authors

ARAnan Abu Rmilah GLGrace Lin KBKebede H. Begna

Discussion

Member takes

Overview

TKI use was associated with QTc prolongation; leaves open whether routine ECG monitoring reduces arrhythmia risk in cancer patients.

Structured PICO

Does tyrosine kinase inhibitor therapy cause QTc prolongation and life-threatening arrhythmias in cancer patients?

Population

618 cancer patients treated with TKI therapy at Mayo Clinic between January 2005 and December 2018, with at least two ECGs (before and after TKI).

Intervention

Tyrosine kinase inhibitors (TKIs) including pazopanib, sunitinib, imatinib, nilotinib, and dasatinib

Outcome

Incidence of QTc prolongation (QTcF ≥450 ms in men, ≥470 ms in women) and life-threatening complications (ventricular tachycardia, sudden cardiac death, Torsade de Pointes)safety

TKI therapy in cancer patients is associated with a high incidence of QTc prolongation (~30%) and a small but significant risk of life-threatening arrhythmias, supporting routine ECG monitoring.

Cite This Study

Rmilah et al. (2020) studied this question.

synapsesocial.com/papers/69deb3b740ea06567955927a https://doi.org/10.1002/ijc.33119

View Full Paper

Ask AI

Bookmark

May 25, 2020International Journal of CancerOpen Access

Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors

View Full Paper

Ask AI

Bookmark

Why the study?

QTc interval prolongation can occur with tyrosine kinase inhibitors, but comparative real-world analyses on its incidence and complication rates are scarce.

Does tyrosine kinase inhibitor therapy cause QTc prolongation and life-threatening arrhythmias in cancer patients?

Population

618 cancer patients treated with TKI therapy with at least two ECGs at Mayo Clinic

Comparison

Different TKI types

Design

Retrospective cohort study

Authors

ARAnan Abu Rmilah GLGrace Lin KBKebede H. Begna

Discussion

Member takes

Overview

TKI use was associated with QTc prolongation; leaves open whether routine ECG monitoring reduces arrhythmia risk in cancer patients.

Structured PICO

Does tyrosine kinase inhibitor therapy cause QTc prolongation and life-threatening arrhythmias in cancer patients?

Population

618 cancer patients treated with TKI therapy at Mayo Clinic between January 2005 and December 2018, with at least two ECGs (before and after TKI).

Intervention

Tyrosine kinase inhibitors (TKIs) including pazopanib, sunitinib, imatinib, nilotinib, and dasatinib

Outcome

Incidence of QTc prolongation (QTcF ≥450 ms in men, ≥470 ms in women) and life-threatening complications (ventricular tachycardia, sudden cardiac death, Torsade de Pointes)safety

TKI therapy in cancer patients is associated with a high incidence of QTc prolongation (~30%) and a small but significant risk of life-threatening arrhythmias, supporting routine ECG monitoring.

Cite This Study

Rmilah et al. (2020) studied this question.

synapsesocial.com/papers/69deb3b740ea06567955927a https://doi.org/10.1002/ijc.33119

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark